Acute decompensated heart failure

Clinical Data from Reprieve Cardiovascular's Successful First-in-Human Therapy for Acute Heart Failure Presented

Retrieved on: 
Friday, December 13, 2019
Heart diseases, Anatomy, Organ failure, Cardiovascular system, Circulatory system, RTT, Heart failure, Acute decompensated heart failure, Shortness of breath, Cardiomyopathy, Management of heart failure

The results were presented today at the Device Therapies in Heart Failure (D-HF 2019) meeting in Paris, France.

Key Points: 
  • The results were presented today at the Device Therapies in Heart Failure (D-HF 2019) meeting in Paris, France.
  • ADHF is a sudden onset of heart failure symptoms, which typically include difficulty breathing (dyspnea), swelling in the extremities, and fatigue.
  • Reprieve Cardiovascular's Personalized Volume Management System, a second-generation automated fluid management system, is designed to better manage diuretic therapy for patients with Acute Decompensated Heart Failure (ADHF) and may relieve a number of symptoms related to this condition.
  • Reprieve Cardiovascular is a pioneering medical device company focused on automated fluid management technologies for acute heart failure treatment.

Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 26, 2019
Articles, Natural sciences, Health, Communication, Forward-looking statement, Pharmaceutical industry in China, Pharmacology, Medication, Acute decompensated heart failure

Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally.

Key Points: 
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally.
  • Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.
  • Such forward-looking statements include statements about the upcoming conferences and Arena's drive, assets, programs, licenses, and partnerships.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized

Retrieved on: 
Tuesday, November 12, 2019
Anatomy, Organ failure, Heart diseases, Heart failure, RTT, Acute decompensated heart failure, Cardiology, Piotr Ponikowski, Aly Saad

The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized.

Key Points: 
  • The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized.
  • "Acute decompensated heart failure is one of the fastest-growing diseases in the world and a leading cause of hospital admissions worldwide with high short term mortality and rehospitalization.
  • Unlike chronic heart failure, there is no established therapy available that improves clinical outcomes in acute heart failure," said Adriaan Voors, Professor of Cardiology, University Medical Center Groningen, Netherlands.
  • Heart failure is highly prevalent in people with diabetes; however, approximately half of all people with heart failure do not have diabetes.

Arena Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 5, 2019
Articles, Health, Natural sciences, Communication, Forward-looking statement, Pharmaceutical industry, Pharmaceutical industry in China, Pharmacology, Medication, Acute decompensated heart failure

Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally.

Key Points: 
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology to patients globally.
  • Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.
  • Such forward-looking statements include statements about the upcoming conferences and Arena's drive, assets, programs, licenses, and partnerships.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Global Acute Decompensated Heart Failure (ADHF) Markets 2019: Disease Background, Treatment, Epidemiology, Marketed Drugs, Pipleine, Deals, Revenues & Landscape

Retrieved on: 
Thursday, June 27, 2019
Anatomy, Heart diseases, Organ failure, Cardiovascular system, Medical specialties, RTT, Acute decompensated heart failure, Heart failure, Levosimendan

DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Acute Decompensated Heart Failure (ADHF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Acute Decompensated Heart Failure (ADHF)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.
  • Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C.
  • The majority of approved therapies are administered via the intravenous route, with one drug also being available in an oral formulation.

Global Acute Decompensated Heart Failure (ADHF) Market Spotlight 2019: Bayer Leads Industry Sponsors with the Highest Number of Clinical Trials, Followed by Scios - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 27, 2019
Health, Cardiology, Anatomy, Heart diseases, Organ failure, Cardiovascular system, Medical specialties, Acute decompensated heart failure, Heart failure, Levosimendan

The "Market Spotlight: Acute Decompensated Heart Failure (ADHF)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Acute Decompensated Heart Failure (ADHF)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.
  • Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C.
  • Bayer leads industry sponsors with the highest number of clinical trials for ADHF, followed by Scios.

Reprieve Cardiovascular Announces Late-Breaking Acute Heart Failure Clinical Trial Data

Retrieved on: 
Saturday, May 25, 2019
Health, Biotechnology, Cardiology, Medical devices, Other Health, Heart diseases, Organ failure, Acute decompensated heart failure

Reprieve Cardiovascular , a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), today announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF).

Key Points: 
  • Reprieve Cardiovascular , a pioneering medical device company focused on improving outcomes for patients suffering from Acute Decompensated Heart Failure (ADHF), today announced the results of two non-randomized, prospective clinical trials in patients hospitalized with Acute Heart Failure (AHF).
  • The data reported a significant increase in diuresis, net negative fluid balance, improved kidney function and improvement in clinical symptoms.
  • Reprieve Cardiovascular is a pioneering medical device company focused on automated fluid management technologies for acute heart failure.
  • Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc. For more information, visit www.reprievecardio.com and follow Reprieve Cardiovascular on Twitter at @ReprieveCardio.

Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

Retrieved on: 
Saturday, March 16, 2019
Medicine, Branches of biology, Health, Heart diseases, Organ failure, Aging-associated diseases, RTT, Heart failure, Herbalism, ACE inhibitor, Medication, Acute decompensated heart failure

"Data from this 4-week extension of PIONEER-HF clearly support Entresto as a first-choice treatment upon systolic heart failure diagnosis or worsening of symptoms and underscore the importance of initiating Entresto in the hospital."

Key Points: 
  • "Data from this 4-week extension of PIONEER-HF clearly support Entresto as a first-choice treatment upon systolic heart failure diagnosis or worsening of symptoms and underscore the importance of initiating Entresto in the hospital."
  • Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant.
  • Patients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine.
  • Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress

Retrieved on: 
Thursday, February 7, 2019
Health sciences, Life sciences, Pharmaceutical sciences, Pharmacy, Pharmaceutical industry, Pharmacology, Medication, Pharmacokinetics, Acute decompensated heart failure

Olorinab is an investigational compound that is not approved for any use in any country.

Key Points: 
  • Olorinab is an investigational compound that is not approved for any use in any country.
  • Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.
  • Arena continues to assess other earlier research and development stage drug candidates, including APD418 for decompensated heart failure.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Medicure Announces Agreement to Market ReDS™ Device for Congestive Heart Failure Patients in the United States

Retrieved on: 
Monday, January 28, 2019
Anatomy, RTT, Circulatory system, Cardiovascular system, Heart diseases, Organ failure, Heart failure, Heart, Acute decompensated heart failure

ReDS is a non-invasive, FDA-cleared medical device that provides an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure.

Key Points: 
  • ReDS is a non-invasive, FDA-cleared medical device that provides an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure.
  • ReDS is already marketed to U.S. hospitals by Sensible and Medicure expects to begin marketing ReDS immediately using its existing commercial organization.
  • "Medicure is pleased to introduce the ReDS device in an effort to improve the quality of life of heart failure patients.
  • ReDS is indicated for patients: with fluid management problems; taking diuretic medication; living with heart failure; or recovering from a coronary artery disease related event.